venetoclax
The European Commission has granted Marketing Authorization for the expanded use of ibrutinib.
The analysis results have clinical implications, as venetoclax-based regimens are the standard of care for patients.
Of 23 patients, three achieved complete remission and 15 achieved complete remission with incomplete hematological recovery.
Three-year follow-up data from the CAPTIVATE trial were presented at the 2022 ASCO Annual Meeting.
The study included adults with treatment-naïve and relapsed/refractory CLL or small lymphocytic leukemia.
The results did not provide any clear benefit by adding venetoclax in patients with previously untreated follicular lymphoma.
The triplet combination resulted in a composite complete remission rate of 91%.
This article reviews the proposed mechanisms of action of venetoclax in AML and the potential future of venetoclax in AML.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.